Loading company details…
metaLinear is a biotechnology company that identifies and validates novel drug targets for difficult Sign up to read more
| Allotment | Filed | Share Class | Round Size | Round Type |
|---|---|---|---|---|
2019-11-19 | £48k |
| Shareholder | Share class | Shares | Holding |
|---|---|---|---|
| PAUL KO FERRIGNO | ORDINARY | 1,480,568 | 41.3% |
| 8888888888888888888888 | 8888888888 | 8888888 | 88888 |
| 88888888888888888888888888 | 8888888888 | 8888888 | 88888 |
| 888888888888888888 | 8888888888 | 888888 | 8888 |
3 more shareholders on file , sign up free to see.
Companies with the most similar business descriptions.
Capital raised per employee divides the equity METALINEAR LIMITED raised in the last six months by the headcount in its most recent filed accounts. It is a rough read on how capital-intensive the business is: a high figure means the company is raising a lot relative to the number of people it employs, which is typical of hardware, biotech and other research-heavy businesses. Headcount comes from annual accounts and so lags the funding date, often by a year or more.
These are the directors and secretaries who have left METALINEAR LIMITED. A resignation is filed with Companies House on form TM01 and the date below is the date the officer's appointment ended, not the date it was filed. Departures matter for reading a company's history: a founder leaving shortly after a funding round, or several directors resigning at once, is often the visible trace of a change of control or a restructure.